Compare · MDT vs OM
MDT vs OM
Side-by-side comparison of Medtronic plc. (MDT) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $100.08B, about 1173.7x OM ($85.3M).
- Over the past year, MDT is down 5.2% and OM is down 74.8% - MDT leads by 69.6 points.
- MDT has been more active in the news (18 items in the past 4 weeks vs 14 for OM).
- MDT has more recent analyst coverage (25 ratings vs 13 for OM).
- Company
- Medtronic plc.
- Outset Medical Inc.
- Price
- $81.14+3.96%
- $4.87+6.10%
- Market cap
- $100.08B
- $85.3M
- 1M return
- +4.35%
- +1.67%
- 1Y return
- -5.22%
- -74.82%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 18
- 14
- Recent ratings
- 25
- 13
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest MDT
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
- morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)
Latest OM
- Outset Medical Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Outset Medical Inc.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chair and CEO Trigg Leslie sold $12,746 worth of shares (3,445 units at $3.70), decreasing direct ownership by 3% to 98,874 units (SEC Form 4) to satisfy tax liability
- EVP Operations R&D & Service Nash Marc sold $5,853 worth of shares (1,582 units at $3.70), decreasing direct ownership by 4% to 38,393 units (SEC Form 4) (tax withholding)
- General Counsel Brottem John L. sold $9,761 worth of shares (2,638 units at $3.70), decreasing direct ownership by 8% to 30,277 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Large owner Leonard Braden Michael exercised 323,000 in-the-money shares at a strike of $5.00 (SEC Form 4)
- SEC Form 144 filed by Outset Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.